AN ARTIFICIAL SEQUENCE-BASED PROTEIN RECEPTOR ARRAY

Information

  • Research Project
  • 6294308
  • ApplicationId
    6294308
  • Core Project Number
    R43GM062700
  • Full Project Number
    1R43GM062700-01
  • Serial Number
    62700
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/2001 - 24 years ago
  • Project End Date
    3/31/2002 - 23 years ago
  • Program Officer Name
    EDMONDS, CHARLES G.
  • Budget Start Date
    9/1/2001 - 24 years ago
  • Budget End Date
    3/31/2002 - 23 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/27/2001 - 24 years ago
Organizations

AN ARTIFICIAL SEQUENCE-BASED PROTEIN RECEPTOR ARRAY

DESCRIPTION (applicant's abstract): Our goal under this SBIR is to demonstrate the feasibility of using a novel Artificial Sequence-based Protein REceptor (ASPIRE) for the creation of a "protein chip." The development of new protein separation technology is essential to bridge the gap between genomics and rational disease diagnostics and treatment. Preliminary results indicate that we can design an artificial receptor, based solely on the predicted protein sequence, capable of purifying a target protein from a cell lysate. To prove that such a receptor will be useful for large-scale high-throughput proteome separation and analysis, we plan to 1) demonstrate that the technology is applicable to 6-10 representative proof of principle proteins; 2) optimize the critical receptor properties for efficient separation of complex samples; and 3) create an array of receptors capable of separating labeled proteins. Our data indicate that a chip based on the ASPIRE technology will be roughly 250x faster and lOx more sensitive than two-dimensional gel electrophoresis paired with mass spectrometry. In addition to the analysis of protein expression patterns, ASPIRE protein chips will allow researchers to conduct large-scale parallel analysis of posttranslational modifications and intracellular trafficking control much of cell regulation. We expect that this technology will have far-reaching implications for basic research, drug development, and disease diagnosis. PROPOSED COMMERCIAL APPLICATION: The market for proteomics is estimated at $4 billion and is rapidly growing. A protein chip enabling proteomics would allow for 1) rapid identification of molecular causes of disease and therapeutic targets 2) efficient screening of small molecules for therapeutic efficacy and toxicity, and 3) rational diagnostic and treatment strategies based on individual molecular profiling.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    108000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:108000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ASPIRA BIOSYSTEMS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SOUTH SAN FRANCISCO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94080
  • Organization District
    UNITED STATES